Circulating 1‐Methylnicotinamide Predicts Dupilumab Response in Adult Asthma: A Prediction Model

Key Points

• To evaluate the predictive ability of circulating 1-methylnicotinamide for dupilumab response in adult asthma patients.
• Measured plasma levels of 1-methylnicotinamide and FeNO in adult asthma patients receiving dupilumab.
• Analyzed predictive accuracy of these biomarkers for treatment response.
• Plasma 1-methylnicotinamide levels were significantly higher in dupilumab responders.
• Combining 1-methylnicotinamide with FeNO resulted in the highest predictive accuracy for treatment response.